

Guardant Health



Investors Menu

[View All News](#)

## GUARDANT HEALTH TO SHOWCASE NEW DATA AT ESMO 2022 DEMONSTRATING UTILITY OF ITS PORTFOLIO OF BLOOD TESTS FOR ADVANCED-STAGE CANCER PATIENTS

September 6, 2022

*Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers*

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, September 9-13 in Paris, France. Among the seven abstracts are an oral presentation and posters highlighting the use of Guardant Health's blood tests and real-world evidence dataset to advance cancer therapy trials, predict and monitor patient response to therapy, and identify genomic mechanisms of acquired resistance to cancer therapy.

"We look forward to sharing new data at ESMO demonstrating the utility of our blood tests to increase the  
Guardant - EXHIBIT 2017

Tempus AI, Inc. v. Guardant Health, Inc.

IPR2025-01435

01

understanding of potential new biomarker targets and the mechanisms of therapy resistance in patients with cancer,” said Helmy Eltoukhy, Guardant Health co-CEO. “The data from retrospective and real-world analyses show how comprehensive genomic profiling tests provide critical insights at every step of a patient’s treatment journey, and ultimately contribute to the development of more effective therapies and improved patient outcomes.”

## Full List of Guardant Health Presentations

### GuardantOMNI

- Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study (Oral Presentation 316O)
- Interim biomarker analysis of a phase 1b/2 study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE) (Presentation 111P)
- Clinical potential of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC) (Presentation 1092P)
- Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC) (Presentation 397P)
- The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts) (Presentation 366P)

### Guardant360

- Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (Presentation 1008P)

### GuardantINFORM

- Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations (Presentation 1407P)

The full abstracts are available on the official [ESMO 2022](#) website.

## About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and

GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit [guardanthealth.com](https://guardanthealth.com) and follow the company on [LinkedIn](#) and [Twitter](#).

## Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220906005434/en/): <https://www.businesswire.com/news/home/20220906005434/en/>

### Investor Contact:

Alex Kleban

[investors@guardanthealth.com](mailto:investors@guardanthealth.com)

+1 657-254-5417

### Media Contact:

Michele Rest

[press@guardanthealth.com](mailto:press@guardanthealth.com)

+1 215-910-2138

Source: Guardant Health, Inc.

[View All News](#)

## QUICK LINKS

[SEC Filings](#)

[Investor FAQs](#)

## IR CONTACT

□ [investors@guardanthealth.com](mailto:investors@guardanthealth.com)

## INVESTOR EMAIL ALERTS

[UNSUBSCRIBE](#)

### **Our Company**

[Mission](#)

[Leadership](#)

### **International**

### **Solutions**

[Treatment Selection](#)

[Recurrence Detection](#)

[Early Detection](#)

[Biopharma Solutions](#)

### **Careers**

[Join Our Mission](#)

[Jobs](#)

### **Investors**

[Press Releases](#)

[Events & Presentations](#)

[Stock Information](#)

[Financials](#)

[Corporate Governance](#)

[Resources](#)

**Guardant Health, Inc.**

505 Penobscot Drive  
Redwood City, CA 94063

**Telephone:** 855.698.8887

**Fax:** 888.974.4258

**Contact us:**

[clientservices@guardanthealth.com](mailto:clientservices@guardanthealth.com)

**Media inquiries:**

[press@guardanthealth.com](mailto:press@guardanthealth.com)

© 2025 Guardant Health

---

[CLIA # 05D2070300](#) | [CAP Accredited # 8765297](#) | [Terms of Use](#) | [Privacy Policy](#) | [Notice of Privacy Practices](#)

Powered By Q4 Inc. 5.167.2.1